MDedge Cardiocast
Download on the App Store

MDedge Cardiocast episodes

  • PCI reduces mortality after STEMI in older adults

    This week in clinical cardiology.

    1. PCI reduces mortality after STEMI in older adults.

    2. Canagliflozin lowers kidney failure risk in T2D: CREDENCE.

    3. Poor response to statins hikes risk of cardiovascular events.

    4. Low LDL cholesterol may increase women's risk of hemorrhagic stroke

    7 min
  • Alirocumab reduces MIs

    This week in clinical cardiology:

    1. Alirocumab reduces both type 1 and 2 MIs.
    2. Despite failed primary endpoint, MI alert device has predictive value.
    3. Look for alcohol septal ablation in the next HOCM guideline.
    4. FDA: Forty ARBs free of nitrosamines.

    You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at [email protected] and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.

    9 min
  • Too much hype for radial access PCI?

    This week's top stories in clinical cardiology:

    1. Has radial access PCI been overhyped?

    2. Hospital TAVR volume matters to patient survival.

    3. Studies link TMAO to microbiome, reveal new heart disease target.

    4. More chest compression–only CPR leads to increased survival rates.

    You can contact the show by emailing us at [email protected] or you can follow MDedge Cardiology on Twitter at @MDedgeCardio.

    10 min
  • Ticagrelor reversal and certification changes

    This week, a novel drug that reverses ticagrelor's effect looks promising, a new certification process for cardiologists is unveiled, intensive blood pressure monitoring may not help prevent a second stroke, and the FDA cautions against using paclitaxel coated devices.

    8 min
  • Top News from ACC 19

    Cardiovascular prevention guidelines downgrade aspirin, high coronary artery calcium scores carry greater risks, an Apple Watch algorithm predicts AFib, and TAVR overtakes surgery in "historic" trials.

    9 min
  • New LDL-lowering drug is under FDA review

    This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.

    7 min
  • Forget what you learned about infective endocarditis

    This week in MDedge Cardiocast: Infective endocarditis isn't what it used to be, there's a new, lower goal for Americans' dietary intake of sodium, a drug to treat myeloma also raises heart failure risk, and Big Pharma says it can't drop drug list prices alone.

    7 min
  • A weight-loss drug is poised for expanded indication

    The Food and Drug Administration could extend eligibility for Belviq to lower-risk patients, the agency says a popular gout drug raises cardiovascular risk, an AHA statement targets CV risk factors in children, and a class action suit against the American Board of Internal Medicine over MOC gets financial support from doctors.

    7 min
  • What comes first with SGLT2 inhibitors – diabetes or heart failure?

    This week in MDedge Cardiocast: Most tPA-eligible stroke patients now get treated within an hour, LAA closure can be treated safely in patients with prior hemorrhagic stroke, SGLT2 inhibitors are quickly morphing from diabetes to heart failure drugs, and the MESA cardiovascular disease risk calculator can be an improvement on the ACC/AHA version.

    9 min

About MDedge Cardiocast

From the publisher's feed

MDedge Cardiocast is the weekly podcast from Cardiology News. The information in this podcast is provided for informational and educational purposes only.